Abbott Laboratories (ABT) - Total Liabilities
Based on the latest financial reports, Abbott Laboratories (ABT) has total liabilities worth $32.92 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ABT cash flow metrics to assess how effectively this company generates cash.
Abbott Laboratories - Total Liabilities Trend (1985–2024)
This chart illustrates how Abbott Laboratories's total liabilities have evolved over time, based on quarterly financial data. Check ABT cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Abbott Laboratories Competitors by Total Liabilities
The table below lists competitors of Abbott Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Salesforce.com Inc
NYSE:CRM
|
USA | $53.16 Billion |
|
Deutsche Telekom AG
XETRA:DTE
|
Germany | €195.56 Billion |
|
Deere & Company
NYSE:DE
|
USA | $77.08 Billion |
|
BlackRock Inc
NYSE:BLK
|
USA | $108.46 Billion |
|
Deutsche Telekom AG
F:DTEA
|
Germany | €195.56 Billion |
|
Union Pacific Corporation
NYSE:UNP
|
USA | $51.23 Billion |
|
Airbus Group SE
PA:AIR
|
France | €102.33 Billion |
|
Shopify Inc
TO:SHOP
|
Canada | CA$1.71 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Abbott Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Abbott Laboratories stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.52 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abbott Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abbott Laboratories (1985–2024)
The table below shows the annual total liabilities of Abbott Laboratories from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.51 Billion | -2.54% |
| 2023-12-31 | $34.39 Billion | -8.38% |
| 2022-12-31 | $37.53 Billion | -4.18% |
| 2021-12-31 | $39.17 Billion | -0.94% |
| 2020-12-31 | $39.55 Billion | +8.09% |
| 2019-12-31 | $36.59 Billion | +0.37% |
| 2018-12-31 | $36.45 Billion | -19.27% |
| 2017-12-31 | $45.15 Billion | +41.33% |
| 2016-12-31 | $31.95 Billion | +60.38% |
| 2015-12-31 | $19.92 Billion | +1.45% |
| 2014-12-31 | $19.64 Billion | +11.03% |
| 2013-12-31 | $17.69 Billion | -56.25% |
| 2012-12-31 | $40.42 Billion | +13.07% |
| 2011-12-31 | $35.75 Billion | -3.34% |
| 2010-12-31 | $36.99 Billion | +25.30% |
| 2009-12-31 | $29.52 Billion | +18.36% |
| 2008-12-31 | $24.94 Billion | +13.70% |
| 2007-12-31 | $21.94 Billion | -0.85% |
| 2006-12-31 | $22.12 Billion | +50.24% |
| 2005-12-31 | $14.73 Billion | +1.97% |
| 2004-12-31 | $14.44 Billion | +5.85% |
| 2003-12-31 | $13.64 Billion | +0.36% |
| 2002-12-31 | $13.59 Billion | -4.51% |
| 2001-12-31 | $14.24 Billion | +112.10% |
| 2000-12-31 | $6.71 Billion | -4.70% |
| 1999-12-31 | $7.04 Billion | -6.12% |
| 1998-12-31 | $7.50 Billion | +6.23% |
| 1997-12-31 | $7.06 Billion | +12.01% |
| 1996-12-31 | $6.31 Billion | +25.71% |
| 1995-12-31 | $5.02 Billion | +12.10% |
| 1994-12-31 | $4.47 Billion | +11.48% |
| 1993-12-31 | $4.01 Billion | +11.69% |
| 1992-12-31 | $3.59 Billion | +17.73% |
| 1991-12-31 | $3.05 Billion | +11.82% |
| 1990-12-31 | $2.73 Billion | +28.44% |
| 1989-12-31 | $2.13 Billion | -9.97% |
| 1988-12-31 | $2.36 Billion | +2.98% |
| 1987-12-31 | $2.29 Billion | +9.85% |
| 1986-12-31 | $2.09 Billion | +30.61% |
| 1985-12-31 | $1.60 Billion | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more